Published Review and Analyst Report Boost TapImmune Shares
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 11/18/14 -- TapImmune, Inc. (OTCQB: TPIV) was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, Ph.D.
Dr. Wilson, in an with Life Sciences Intellectual Property Review, estimates the Seattle-based company will be worth more than $1 billion in just five years.
The U.K. Based Life Sciences Intellectual Property Review tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences.
Dirks Research, in a separate report released on Monday, said that an official announcement regarding the start of Phase II clinical trials for TapImmune''s immunotherapy cancer vaccines for Breast and Ovarian cancer is imminent.
Analysts also noted that a push of the company''s development pipeline into Phase II for two urgently needed therapeutic indications, each with blockbuster potential and huge market opportunities simultaneously, would likely create an inflection point in prices and valuation for the Seattle based firm.
In a recent quarterly filing, officials at TapImmune indicated that they planned to initiate the two pending Phase II studies in Q4 of 2014.
BioMedReports is a news and research portal covering for the entire of the market. Full disclosures and information about the stocks and information mentioned in this news release are available at BioMedReports.Com
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company''s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient''s killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company''s website at for details.
M. Davila
Assistant Editor
BioMedReports.Com
e-mail:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2014 - 07:30 Uhr
Sprache: Deutsch
News-ID 1319269
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 165 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Published Review and Analyst Report Boost TapImmune Shares
"
steht unter der journalistisch-redaktionellen Verantwortung von
TapImmune, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
